- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–224
of 224
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Angioedema
- Interventions
- Factor XIIa antagonist monoclonal antibody, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
- Conditions
- Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
- Interventions
- Patch Testing
- Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Urticaria
- Interventions
- Test Drug (JDP-205), Active Control (Diphenhydramine)
- Drug
- Lead sponsor
- JDP Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Hereditary Angioedema
- Interventions
- C1 esterase inhibitor [human] (C1INH-nf)
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 48
- States / cities
- Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
- Conditions
- Includes: Hereditary Angioedema
- Interventions
- Berinert® (C1 Esterase Inhibitor)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- Ecallantide subcutaneous dosing
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia